Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- rectus femoris spasticity (> Ashworth 2)
- able to walk on treadmill
- stiff knee gait improved after rectus femoris diagnostic motor nere block
- ...
- rectus femoris spasticity (> Ashworth 2)
- able to walk on treadmill
- stiff knee gait improved after rectus femoris diagnostic motor nere block
- stroke lasting for more than 6 months
- transient improvement with previous botulinum toxine A injection in the rectus femoris
- stiff knee gait
Exclusion Criteria
- previous surgery for stiff knee gait
- botulinum toxin A injections in the rectus femoris < 6 months
- pregnant women
- previous surgery for stiff knee gait
- botulinum toxin A injections in the rectus femoris < 6 months
- pregnant women
Summary
- Conditions
- Spasticity
- Stroke
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
INTRODUCTION Stroke is the third cause of death and the leading cause of handicap among industrialized countries. Spasticity and co-contraction of the rectus femoris muscle following stroke is responsible for a lack of knee flexion in the swing phase of gait named stiff knee gait. The rectus femoris...
INTRODUCTION Stroke is the third cause of death and the leading cause of handicap among industrialized countries. Spasticity and co-contraction of the rectus femoris muscle following stroke is responsible for a lack of knee flexion in the swing phase of gait named stiff knee gait. The rectus femoris spasticity is usually treated by oral medications, physical therapy and botulinum toxin A injections (1,2). As botulinum toxin A has a transient effect, injections must be repeated supporting to promote a permanent surgical treatment such as the rectus femoris tenotomy (3). However, no study has evaluate neither compare the effect of the rectus femoris tenotomy on gait and on the 3 domains of the International Classification of Functioning Disability and Health . OBJECTIVE To compare the effect of the rectus femoris tenotomy and of the botulinum toxin A injections for stiff knee gait after stroke according to the 3 domains of the International Classification of Functioning Disability and Health METHODS The investigators will recruited 20 chronic stroke patients presenting with stiff knee gait. The patients will be randomly assigned to a surgical group treated by rectus femoris tenotomy (10 patients) and to a medical group treated by rectus femoris botulinum toxin A injections. Patients will be assessed before treatment, 2 months and 6 months after treatment by an assessor blinded therapist among the 3 domains of the International Classification of Functioning Disability and Health PERSPECTIVE The investigator hope to demonstrate the effectiveness of the rectus femoris tenotomy as a treatment of stiff knee gait after stroke
Inclusion Criteria
- rectus femoris spasticity (> Ashworth 2)
- able to walk on treadmill
- stiff knee gait improved after rectus femoris diagnostic motor nere block
- ...
- rectus femoris spasticity (> Ashworth 2)
- able to walk on treadmill
- stiff knee gait improved after rectus femoris diagnostic motor nere block
- stroke lasting for more than 6 months
- transient improvement with previous botulinum toxine A injection in the rectus femoris
- stiff knee gait
Exclusion Criteria
- previous surgery for stiff knee gait
- botulinum toxin A injections in the rectus femoris < 6 months
- pregnant women
- previous surgery for stiff knee gait
- botulinum toxin A injections in the rectus femoris < 6 months
- pregnant women
Tracking Information
- NCT #
- NCT02114736
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Thierry Deltombe, M.D. University Hospital of Mont-Godinne, Université Catholique de Louvain
- Thierry Deltombe, M.D. University Hospital of Mont-Godinne, Université Catholique de Louvain